source
- Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleyEli Lilly said on Thursday it will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, in a move that further spotlights big pharma’s increasing interest in the space after years o…Endpoints · 15d ago↗ source
- Updated: Merck beats AstraZeneca to approval for first PCSK9 pillAs in football, so in pharmaceuticals: The English have been beaten. Merck has outpaced AstraZeneca in the race to get the first US approval for an oral form of a particular kind of cholesterol-low…Endpoints · 15d ago↗ source
- Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 updateTakeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.